#1 Clinical Trials Search in Europe

Pitolisant

Pitolisant, a novel drug that acts as a histamine H3 receptor antagonist/inverse agonist, is being extensively studied in clinical trials for its potential to treat various sleep disorders and other conditions. This article explores the ongoing research into pitolisant’s efficacy and safety across different patient populations, including those with narcolepsy, idiopathic hypersomnia, and autism spectrum disorders.

Table of Contents

What is Pitolisant?

Pitolisant, also known by its brand name Wakix or BF2.649, is a medication that belongs to a class of drugs called histamine H3 receptor antagonists/inverse agonists[1]. It is primarily used to treat excessive daytime sleepiness and cataplexy (sudden loss of muscle tone) in people with narcolepsy, a chronic sleep disorder[2].

What Conditions Does Pitolisant Treat?

Pitolisant is approved and being studied for several conditions:

  • Narcolepsy with or without cataplexy: This is the primary condition for which pitolisant is used. Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness and, in some cases, sudden loss of muscle tone (cataplexy)[3].
  • Idiopathic Hypersomnia: A sleep disorder characterized by excessive daytime sleepiness despite normal or prolonged nighttime sleep[4].
  • Restless Legs Syndrome (RLS): A condition that causes an uncomfortable sensation and an urge to move the legs, typically in the evening or nighttime[5].
  • Autism Spectrum Disorder: Pitolisant is being studied for its potential effects on social responsiveness in children and adolescents with autism[1].

How Does Pitolisant Work?

Pitolisant works by targeting the histamine system in the brain. Specifically, it acts as an antagonist/inverse agonist at histamine H3 receptors. This means it blocks these receptors and may also reverse their normal activity. By doing so, pitolisant increases the release of histamine in the brain, which helps promote wakefulness and alertness[1].

Dosage and Administration

Pitolisant is typically taken orally once daily in the morning upon wakening. The dosage can vary depending on the condition being treated and individual patient factors. In clinical trials, the following dosing strategies have been observed:

  • For narcolepsy in adults: Starting dose of 8.9 mg, which can be increased weekly up to a maximum of 35.6 mg[4].
  • For children and adolescents: Dosing is being studied and may range from 5 mg to 40 mg per day[1][6].

It’s important to note that dosage should always be determined by a healthcare provider based on individual patient needs and responses.

Ongoing Clinical Trials

Pitolisant is currently being studied in several clinical trials to explore its effectiveness in various conditions:

  • Long-term safety and effectiveness in idiopathic hypersomnia: A study to assess the long-term effects of pitolisant in patients with idiopathic hypersomnia[4].
  • Refractory Restless Legs Syndrome: An open-label trial to evaluate pitolisant as an adjunct therapy for patients with RLS who haven’t responded adequately to standard treatments[5].
  • Autism Spectrum Disorders in children and adolescents: A study to investigate the effect of pitolisant on social responsiveness in young people with autism[1].
  • Type 1 Diabetes: A study to assess the safety, tolerability, and effects of pitolisant on blood sugar control in patients with Type 1 Diabetes[7].
  • Alcohol Use Disorder: A trial to test the effect of pitolisant on alcohol consumption and craving in heavy drinkers[8].

Potential Side Effects

As with all medications, pitolisant may cause side effects. Common side effects reported in clinical trials include:

  • Headache
  • Nausea
  • Insomnia
  • Anxiety

However, it’s important to note that not everyone experiences side effects, and your doctor will monitor you closely for any adverse reactions[4].

Use in Special Populations

Pregnancy: A pregnancy registry has been established to study the effects of pitolisant exposure during pregnancy. This observational study aims to evaluate the safety of pitolisant use in pregnant women and their offspring[9].

Children and Adolescents: Clinical trials are ongoing to assess the safety and efficacy of pitolisant in pediatric populations, particularly for narcolepsy and autism spectrum disorders[6][1].

Aspect Details
Drug Name Pitolisant (also known as BF2.649, Wakix)
Mechanism of Action Histamine H3 receptor antagonist/inverse agonist
Conditions Studied Narcolepsy (with and without cataplexy), Idiopathic Hypersomnia, Excessive Daytime Sleepiness, Restless Legs Syndrome, Autism Spectrum Disorders
Administration Oral tablet, typically once daily in the morning
Dosage Range 4.45 mg to 35.6 mg (varies by study)
Primary Outcomes Changes in excessive daytime sleepiness, frequency of cataplexy attacks, safety assessments
Patient Populations Adults, children, and adolescents (depending on the study)
Study Designs Randomized, double-blind, placebo-controlled trials; open-label studies

FAQ

  • What is pitolisant and how does it work? Pitolisant is a histamine H3 receptor antagonist/inverse agonist. It works by increasing histamine levels in the brain, which helps promote wakefulness and alertness.
  • What conditions is pitolisant being studied for in clinical trials? Pitolisant is being studied for various conditions, including narcolepsy with and without cataplexy, idiopathic hypersomnia, excessive daytime sleepiness, restless legs syndrome, and autism spectrum disorders.
  • How is pitolisant administered in clinical trials? In most trials, pitolisant is administered orally as a tablet, typically once daily in the morning. The dosage may vary depending on the study, ranging from 4.45 mg to 35.6 mg.
  • What are some of the primary outcomes being measured in pitolisant trials? Primary outcomes often include changes in excessive daytime sleepiness (measured by scales like the Epworth Sleepiness Scale), frequency of cataplexy attacks, and safety assessments through monitoring of adverse events.
  • Are there any ongoing studies of pitolisant in pediatric populations? Yes, there are ongoing studies evaluating the safety and efficacy of pitolisant in children and adolescents with narcolepsy and autism spectrum disorders.

Ongoing Clinical Trials on Pitolisant

  • Study of the effects of pitolisant on migraine without aura in women

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on the Safety and Effectiveness of Pitolisant for Children Aged 6-17 with Narcolepsy, with or without Cataplexy

    Not recruiting

    3 1 1
    Investigated drugs:
    France Italy

  • Study on the Effects of Pitolisant for Children and Adolescents with Autism Spectrum Disorder

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland Spain

Glossary

  • Pitolisant: A drug that acts as a histamine H3 receptor antagonist/inverse agonist, being studied for various sleep disorders and other conditions.
  • Narcolepsy: A chronic sleep disorder characterized by excessive daytime sleepiness and sudden attacks of sleep.
  • Cataplexy: A sudden and transient episode of muscle weakness triggered by strong emotions, often associated with narcolepsy.
  • Idiopathic Hypersomnia: A sleep disorder characterized by excessive daytime sleepiness without a known cause.
  • Excessive Daytime Sleepiness (EDS): A condition where a person feels very sleepy during the day and has a difficult time staying awake and alert.
  • Epworth Sleepiness Scale (ESS): A questionnaire used to measure a person's general level of daytime sleepiness.
  • Autism Spectrum Disorder (ASD): A developmental disorder that affects communication and behavior.
  • Restless Legs Syndrome (RLS): A condition that causes an uncontrollable urge to move the legs, usually due to discomfort.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT05953389
  2. https://clinicaltrials.gov/study/NCT01800045
  3. https://clinicaltrials.gov/study/NCT03433131
  4. https://clinicaltrials.gov/study/NCT05458128
  5. https://clinicaltrials.gov/study/NCT05581576
  6. https://clinicaltrials.gov/study/NCT02611687
  7. https://clinicaltrials.gov/study/NCT04026750
  8. https://clinicaltrials.gov/study/NCT04596267
  9. https://clinicaltrials.gov/study/NCT05536011